 |
|
Cost-effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack
François P. Sarasin, MD;
Jean-Michel Gaspoz, MD, MSc;
Henri Bounameaux, MD
Arch Intern Med. 2000;160:2773-2778.
Background Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack. However, their cost-effectiveness ratios relative to aspirin alone have not been estimated.
Methods We developed a Markov model to measure the clinical benefits and the economic consequences of the following strategies to treat high-risk patients aged 65 years or older: (1) aspirin, 325 mg/d; (2) aspirin, 50 mg/d, and dipyridamole, 400 mg/d; and (3) clopidogrel bisulfate, 75 mg/d. Input data were obtained by literature review. Outcomes were expressed as US dollars per quality-adjusted life-year (QALY).
Results The use of aspirin combined with dipyridamole was more effective and less costly compared with the use of aspirin alone, providing a gain of 0.3 QALY for a 65-year-old patient. This regimen remained cost-effective despite wide sensitivity analyses. Clopidogrel was more effective and more costly compared with aspirin alone, yielding a gain of 0.2 QALY with a marginal cost-effectiveness ratio of $26,580 per each additional QALY (patient aged 65 years). Sensitivity analyses demonstrated that the efficacy of clopidogrel and its cost were key factors in determining its cost-effectiveness ratio compared with aspirin, which exceeded $50,000 when its efficacy decreased by half or its cost doubled.
Conclusion To prevent stroke in high-risk patients, dipyridamole combined with aspirin was more effective and less costly than aspirin alone, and clopidogrel was cost-effective compared with current standards of medical practice, except in extreme scenarios.
From the Medical Clinics 1 and 2, Division of Angiology and Haemostasis, and Groupe de Recherche et d'Analyse en Systèmes et Soins Hospitaliers (GRASSH) (Drs Sarasin and Gaspoz), and the Department of Internal Medicine (Dr Bounameaux), Hôpital Cantonal, University of Geneva Medical School, Geneva, Switzerland.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(18):2872-2873.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Antiplatelet medication management in patients hospitalized with ischemic stroke
Nickman et al.
Am J Health Syst Pharm 2007;64:2250-2256.
ABSTRACT
| FULL TEXT
Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study
Ramsay et al.
J Public Health (Oxf) 2007;29:251-257.
ABSTRACT
| FULL TEXT
Multifaceted implementation of stroke prevention guidelines in primary care: cluster-randomised evaluation of clinical and cost effectiveness
Wright et al.
Qual Saf Health Care 2007;16:51-59.
ABSTRACT
| FULL TEXT
Diabetes Self-management Education Program for Medicaid Recipients: A Continuous Quality Improvement Process
Balamurugan et al.
The Diabetes Educator 2006;32:893-900.
ABSTRACT
| FULL TEXT
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Sacco et al.
Circulation 2006;113:e409-e449.
ABSTRACT
| FULL TEXT
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Sacco et al.
Stroke 2006;37:577-617.
ABSTRACT
| FULL TEXT
The cost of glucocorticoid-associated adverse events in rheumatoid arthritis
Pisu et al.
Rheumatology (Oxford) 2005;44:781-788.
ABSTRACT
| FULL TEXT
Efficacy of Aspirin Plus Extended-Release Dipyridamole in Preventing Recurrent Stroke in High-Risk Populations
Sacco et al.
Arch Neurol 2005;62:403-408.
ABSTRACT
| FULL TEXT
A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus Aspirin Alone
Schleinitz and Heidenreich
ANN INTERN MED 2005;142:251-259.
ABSTRACT
| FULL TEXT
Transcatheter Closure versus Medical Therapy of Patent Foramen Ovale and Presumed Paradoxical Thromboemboli: A Systematic Review
Khairy et al.
ANN INTERN MED 2003;139:753-760.
ABSTRACT
| FULL TEXT
Cost-Effective Outcome for Treating Poor-Grade Subarachnoid Hemorrhage
Wilby et al.
Stroke 2003;34:2508-2511.
ABSTRACT
| FULL TEXT
Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease
Gaspoz et al.
NEJM 2002;346:1800-1806.
ABSTRACT
| FULL TEXT
Cost-effectiveness of Antiplatelet Therapies
Schleinitz
Arch Intern Med 2001;161:1236-1236.
FULL TEXT
Is Treatment With Aspirin Combined With Dipyridamole Really More Cost-effective Than Aspirin Alone?
Heidebrink
Arch Intern Med 2001;161:1236-1236.
FULL TEXT
|
